End-of-day quote
Taipei Exchange
06:00:00 2024-05-06 pm EDT
|
5-day change
|
1st Jan Change
|
123
TWD
|
0.00%
|
|
+1.23%
|
+11.82%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
---|
Capitalization
1 |
9,043
|
9,217
|
7,935
|
7,727
|
7,623
|
8,524
|
Enterprise Value (EV)
1 |
9,043
|
9,217
|
7,935
|
7,727
|
7,623
|
8,524
|
P/E ratio
|
-
|
-
|
-
|
-
|
-
|
-
|
Yield
|
3.07%
|
3.01%
|
-
|
4.04%
|
-
|
-
|
Capitalization / Revenue
|
4,864,938
x
|
4,732,178
x
|
4,346,589
x
|
-
|
-
|
-
|
EV / Revenue
|
4,864,938
x
|
4,732,178
x
|
4,346,589
x
|
-
|
-
|
-
|
EV / EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / FCF
|
18,684,161
x
|
19,918,350
x
|
-97,208,692
x
|
-
|
-
|
-
|
FCF Yield
|
0%
|
0%
|
-0%
|
-
|
-
|
-
|
Price to Book
|
3.64
x
|
3.46
x
|
2.83
x
|
2.55
x
|
2.39
x
|
-
|
Nbr of stocks (in thousands)
|
69,298
|
69,298
|
69,298
|
69,298
|
69,298
|
69,298
|
Reference price
2 |
130.5
|
133.0
|
114.5
|
111.5
|
110.0
|
123.0
|
Announcement Date
|
3/18/20
|
3/17/21
|
3/15/22
|
3/16/23
|
3/12/24
|
-
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
1,613
|
1,859
|
1,948
|
1,825
|
2,010
|
1,945
|
EBITDA
1 |
575.1
|
670.9
|
711
|
662.6
|
698.9
|
721.3
|
EBIT
1 |
489.2
|
580.5
|
606.7
|
547.9
|
578.4
|
580.2
|
Operating Margin
|
30.33%
|
31.23%
|
31.15%
|
30.02%
|
28.77%
|
29.83%
|
Earnings before Tax (EBT)
1 |
515.3
|
592.6
|
601.8
|
538.2
|
623.2
|
569.5
|
Net income
1 |
405
|
464.2
|
488.7
|
431.3
|
493.5
|
452.6
|
Net margin
|
25.11%
|
24.97%
|
25.09%
|
23.62%
|
24.55%
|
23.27%
|
EPS
2 |
5.810
|
6.670
|
7.020
|
6.200
|
7.090
|
6.500
|
Free Cash Flow
1 |
230
|
347.5
|
378
|
-8.474
|
-237.5
|
459.5
|
FCF margin
|
14.26%
|
18.69%
|
19.41%
|
-0.46%
|
-11.81%
|
23.63%
|
FCF Conversion (EBITDA)
|
39.98%
|
51.79%
|
53.16%
|
-
|
-
|
63.7%
|
FCF Conversion (Net income)
|
56.78%
|
74.86%
|
77.35%
|
-
|
-
|
101.53%
|
Dividend per Share
2 |
4.000
|
4.000
|
4.000
|
4.500
|
4.500
|
4.500
|
Announcement Date
|
4/1/19
|
3/18/20
|
3/17/21
|
3/25/22
|
3/16/23
|
3/12/24
|
Fiscal Period: December |
2021 Q3
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2023 Q1
|
2023 Q2
|
---|
Net sales
1 |
443.4
|
-
|
486.5
|
523.7
|
455.9
|
472.3
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
121.5
|
-
|
150.8
|
148
|
123.7
|
127.6
|
Operating Margin
|
27.41%
|
-
|
31.01%
|
28.26%
|
27.13%
|
27.01%
|
Earnings before Tax (EBT)
|
-
|
-
|
161.1
|
169.3
|
124.2
|
-
|
Net income
|
-
|
122.1
|
124.1
|
133.9
|
98.7
|
-
|
Net margin
|
-
|
-
|
25.51%
|
25.56%
|
21.65%
|
-
|
EPS
|
-
|
1.750
|
1.790
|
1.930
|
1.420
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/11/21
|
5/16/22
|
8/12/22
|
11/11/22
|
5/12/23
|
8/11/23
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
484
|
463
|
-81.6
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
19.3%
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
16.3%
|
-
|
-
|
-
|
-
|
-
|
Assets
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
1 |
35.90
|
38.40
|
40.50
|
43.80
|
46.00
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
|
139
|
172
|
551
|
-
|
-
|
-
|
Capex / Sales
|
7.5%
|
8.82%
|
30.18%
|
-
|
-
|
-
|
Announcement Date
|
3/18/20
|
3/17/21
|
3/15/22
|
3/16/23
|
3/12/24
|
-
|
|
1st Jan change
|
Capi.
|
---|
| +11.82% | 263M | | -30.62% | 3.13B | | -15.57% | 2.54B | | +21.75% | 2.55B | | +7.04% | 2.08B | | -1.13% | 2.09B | | -0.56% | 1.51B | | +0.46% | 1.32B | | +23.78% | 1.23B | | +4.01% | 1.14B |
Medical Supplies
|